- Home
- ROOT vs CELC Comparison
ROOT vs CELC Comparison
Compare ROOT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- CELC
- Stock Information
- Founded
- ROOT 2015
- CELC 2011
- Country
- ROOT United States
- CELC United States
- Employees
- ROOT N/A
- CELC 87
- Industry
- ROOT Property-Casualty Insurers
- CELC Medical Specialities
- Sector
- ROOT Finance
- CELC Health Care
- Exchange
- ROOT Nasdaq
- CELC Nasdaq
- Market Cap
- ROOT 2.3B
- CELC 2.8B
- IPO Year
- ROOT 2020
- CELC 2017
- Fundamental
- Price
- ROOT $78.55
- CELC $70.34
- Analyst Decision
- ROOT Buy
- CELC Strong Buy
- Analyst Count
- ROOT 6
- CELC 5
- Target Price
- ROOT $124.40
- CELC $69.40
- AVG Volume (30 Days)
- ROOT 500.1K
- CELC 1.5M
- Earning Date
- ROOT 11-05-2025
- CELC 11-13-2025
- Dividend Yield
- ROOT N/A
- CELC N/A
- EPS Growth
- ROOT N/A
- CELC N/A
- EPS
- ROOT 4.73
- CELC N/A
- Revenue
- ROOT $1,364,700,000.00
- CELC N/A
- Revenue This Year
- ROOT $27.41
- CELC N/A
- Revenue Next Year
- ROOT $9.74
- CELC N/A
- P/E Ratio
- ROOT $16.51
- CELC N/A
- Revenue Growth
- ROOT 59.76
- CELC N/A
- 52 Week Low
- ROOT $36.87
- CELC $7.58
- 52 Week High
- ROOT $181.14
- CELC $83.00
- Technical
- Relative Strength Index (RSI)
- ROOT 38.60
- CELC 71.03
- Support Level
- ROOT $74.67
- CELC $49.80
- Resistance Level
- ROOT $81.49
- CELC $83.00
- Average True Range (ATR)
- ROOT 4.69
- CELC 4.33
- MACD
- ROOT -0.24
- CELC 2.28
- Stochastic Oscillator
- ROOT 22.05
- CELC 66.54
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.